Literature DB >> 17495607

Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation.

Kasuen Wong1, Robert O Ryan.   

Abstract

PURPOSE OF REVIEW: Cardiovascular disease is the leading cause of death in the USA, and hypertriglyceridemia represents an independent risk factor contributing to its premature onset. Apolipoprotein (apo)A-V has been shown to be a potent regulator of plasma triacylglycerol. We highlight structural aspects of apoA-V and discuss recent findings that provide mechanistic insight into its function as a regulator of plasma triacylglycerol metabolism. RECENT
FINDINGS: Recent findings indicate that apoA-V is comprised of two independently folded domains. Fluorescence spectroscopy and truncation analysis revealed that the carboxyl-terminal region functions in apoA-V lipid binding, consistent with its known association with plasma lipoproteins. An indirect triacylglycerol-modulating effect of apoA-V has been attributed to heparan sulfate proteoglycan binding, as confirmed by structural studies. Furthermore, apoA-V has been shown to interact with cell surface receptors, potentially facilitating lipoprotein particle endocytosis.
SUMMARY: Several features of apoA-V, including extremely low plasma concentration, lack of correlation with plasma cholesterol levels despite its association with HDL, and insolubility at neutral pH in the absence of lipid, are unlike those of other exchangeable apolipoproteins. Current and future studies of apoA-V will help to shed light on the molecular basis whereby this protein functions to modulate plasma lipid homeostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495607     DOI: 10.1097/MOL.0b013e328133856c

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  17 in total

Review 1.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

Review 2.  New technologies for delineating and characterizing the lipid exome: prospects for understanding familial combined hyperlipidemia.

Authors:  Stuart D Horswell; Helen E Ringham; Carol C Shoulders
Journal:  J Lipid Res       Date:  2008-11-20       Impact factor: 5.922

3.  Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease.

Authors:  Esther M M Ooi; Doris T Chan; Gerald F Watts; Dick C Chan; Theodore W K Ng; Gursharan K Dogra; Ashley B Irish; P Hugh R Barrett
Journal:  J Lipid Res       Date:  2011-02-06       Impact factor: 5.922

4.  The carboxyl-terminal segment of apolipoprotein A-V undergoes a lipid-induced conformational change.

Authors:  Kasuen Mauldin; Brian L Lee; Marta Oleszczuk; Brian D Sykes; Robert O Ryan
Journal:  Biochemistry       Date:  2010-06-15       Impact factor: 3.162

5.  Apolipoprotein A-V associates with intrahepatic lipid droplets and influences triglyceride accumulation.

Authors:  Xiao Shu; Lisa Nelbach; Robert O Ryan; Trudy M Forte
Journal:  Biochim Biophys Acta       Date:  2010-02-11

6.  Intracellular lipid droplet targeting by apolipoprotein A-V requires the carboxyl-terminal segment.

Authors:  Xiao Shu; Robert O Ryan; Trudy M Forte
Journal:  J Lipid Res       Date:  2008-04-30       Impact factor: 5.922

7.  Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels.

Authors:  S F C Vaessen; G M Dallinga-Thie; C J D Ross; L J Splint; L W Castellani; P C N Rensen; M R Hayden; F G Schaap; J A Kuivenhoven
Journal:  J Lipid Res       Date:  2009-01-13       Impact factor: 5.922

8.  The ins (cell) and outs (plasma) of apolipoprotein A-V.

Authors:  Trudy M Forte; Xiao Shu; Robert O Ryan
Journal:  J Lipid Res       Date:  2008-12-02       Impact factor: 5.922

9.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.

Authors:  Nadeem Sarwar; Manjinder S Sandhu; Sally L Ricketts; Adam S Butterworth; Emanuele Di Angelantonio; S Matthijs Boekholdt; Willem Ouwehand; Hugh Watkins; Nilesh J Samani; Danish Saleheen; Debbie Lawlor; Muredach P Reilly; Aroon D Hingorani; Philippa J Talmud; John Danesh
Journal:  Lancet       Date:  2010-05-08       Impact factor: 79.321

Review 10.  Clinical significance of apolipoprotein A5.

Authors:  E Shyong Tai; Jose M Ordovas
Journal:  Curr Opin Lipidol       Date:  2008-08       Impact factor: 4.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.